We appreciate the continuing interest of Abbasi1 in the PREVEND cohort. Our article showed that in a community-based cohort increased albumin excretion, and not estimated glomerular filtration rate, was associated with incident AF, even after adjustments for established cardiovascular risk factors.2 We agree that we cannot rule out unmeasured confounding or reverse causality. Theoretically, a randomized controlled trial or Mendelian randomization may be approaches to provide more causal evidence.3 However, the Mendelian randomization as brought forward based on GWAS variants are also not immune against unmeasured confounding or reverse causality, simply because the instrumental variable assumptions are not satisfied here (e.g. supported by strong biological understanding). To our knowledge, there is no therapy available that solely targets microalbuminuria that can be investigated to reduce incident AF. In addition, even when such therapies become available a large sample size will be required to perform a randomized trial in the primary prevention setting. The magnitude of associations can indicate the predictive value of a biomarker, in our case albumin excretion. Indeed potential improvements in prediction need to be formally quantified in terms of calibration, discrimination and net reclassification improvement, before increased albumin excretion can be implemented into the risk prediction of incident AF. As a result of such analysis risk prediction schemes, which need external validation, can be build or modified to better identify those at lowest and highest AF risk. This was however not the aim of our analysis. We sought to investigate in our analysis different measures of renal function such as serum creatinine or cystatin C, estimated glomerular filtration rates, and albumin excretion, in relation to development of AF, and whether the magnitude of effect of renal measures and cardiovascular outcome may be influenced by AF.2 Finally, Abbasi brought up an interesting point that there may be a subset of individuals with increased urine albumin that may be considered as high risk for incident AF. Indeed targeting high risk groups specifically may help to reduce their risk of AF. However, more research is needed to study the characteristics of such high risk groups, and which specific therapies are needed. Unfortunately, our number of incident AF cases was rather modest to perform stratified analyses according to different severities of albumin excretion. We hope that our analysis further increases the interest in albumin excretion and its link with AF, and motivate others to help to investigate this further. Such research is warranted to determine whether personalized precision medicine approaches can improve treatment outcomes and minimize adverse events.4 Conflict of interest: none declared. Funding The PREVEND study is supported by the Dutch Kidney Foundation (Grant E0.13) and the Netherlands Heart Foundation (Grant NHS2010B280). Dr Rienstra is supported by a grant from the Netherlands Organization for Scientific Research (Veni Grant 016.136.055). References 1 Abbasi A. Urine albumin excretion and the risk of incident atrial fibrillation: predictive or aetiological relevance? Europace 2018;20:547. 2 Marcos EG, Geelhoed B, Van Der Harst P, Bakker SJL, Gansevoort RT, Hillege HL et al. Relation of renal dysfunction with incident atrial fibrillation and cardiovascular morbidity and mortality: the PREVEND study. Europace 2017;19:1930--6. 3 Chatterjee NA, Giulianini F, Geelhoed B, Lunetta KL, Misialek JR, Niemeijer MN et al. Genetic obesity and the risk of atrial fibrillation: causal estimates from Mendelian randomization. Circulation 2017; 135: 741– 54. Google Scholar CrossRef Search ADS PubMed 4 Van Gelder IC, Hobbelt AH, Marcos EG, Schotten U, Cappato R, Lewalter T et al. Tailored treatment strategies: a new approach for modern management of atrial fibrillation. J Intern Med 2016; 279: 457– 66. Google Scholar CrossRef Search ADS PubMed Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: email@example.com.
Europace – Oxford University Press
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera